Medical progress: Heart failure

New England Journal of Medicine

Volumn 348, Issue 20, 2003, Pages 2007-2018

  Jessup, Mariell ^a   Brozena, Susan ^b  

^a Heart Failure/Transplant Program   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLONIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; MOXONIDINE; NESIRITIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; BRADYCARDIA; BRONCHOSPASM; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DEMOGRAPHY; DIABETES MELLITUS; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KINESIOTHERAPY; LOW DRUG DOSE; MITRAL VALVE REGURGITATION; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; UREMIA; ARTIFICIAL HEART PACEMAKER; BIOLOGICAL MODEL; CLASSIFICATION; CONGESTIVE HEART FAILURE; FEMALE; HOSPITALIZATION; MALE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MODELS, CARDIOVASCULAR; PACEMAKER, ARTIFICIAL; SEVERITY OF ILLNESS INDEX; VENTRICULAR REMODELING;

EID: 0037883399     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra021498     Document Type: Review

References (89)

1. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
2. 2001 Heart and stroke statistical update. Dallas: American Heart Association, 2000.
3. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287:883-9.
4. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-84.
5. Shah NB, Der E, Ruggerio C, Heidenreich PA, Massie BM. Prevention of hospitalizations for heart failure with an interactive home monitoring program. Am Heart J 1998;135:373-8.
6. Konstam MA. Progress in heart failure management? Lessons from the real world. Circulation 2000;102:1076-8.
7. Khand A, Gemmel I, Clark AL, Cleland JG. Is the prognosis of heart failure improving? J Am Coll Cardiol 2000;36:2284-6.
8. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101-13.
9. Gibelin P. An evaluation of symptom classification systems used for the assessment of patients with heart failure in France. Eur J Heart Fail 2001;3:739-46.
10. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure. Circulation 2002;105:2099-106, 2223-8.
11. Mann D. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
12. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-8.
13. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996; 94:2285-96.
14. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72.
15. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
16. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995;91;2573-81.
17. Hall SA, Cigarroa CG, Marcoux L, Risser KC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25: 1154-61.
18. Saxon LA, De Marco T, Schafer J, Chatterjee K, Kumar UN, Foster E. Effects of longterm biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation 2002;105:1304-10.
19. Otsuji Y, Gilon D, Jiang L, et al. Restricted diastolic opening of the mitral leaflets in patients with left ventricular dysfunction: evidence for increased valve tethering. J Am Coll Cardiol 1998;32:398-404.
20. He S, Fontaine AA, Schwammenthal E, Yoganathan AP, Levine RA. Integrated mechanism for functional mitral regurgitation: leaflet restriction versus coapting force: in vitro studies. Circulation 1997;96:1826-34.
21. Van Dantzig JM, Delemarre BJ, Koster RW, Bot H, Visser CA. Pathogenesis of mitral regurgitation in acute myocardial infarction: importance of changes in left ventricular shape and regional function. Am Heart J 1996;131:865-71.
22. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-52.
23. Wenger NK. Oral anticoagulant therapy at elderly age: heart failure and nonvalvular atrial fibrillation. Am J Geriatr Cardiol 1996; 5:78-83.
24. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
25. Rabkin SW, Mathewson FL, Tate RB. The electrocardiogram in apparently healthy men and the risk of sudden death. Br HeartJ 1982;47:546-52.
26. Schneider JF, Thomas HE Jr, McNamara PM, Kannel WB. Clinical-electrocardiographic correlates of newly acquired left bundle branch block: the Framingham study. Am J Cardiol 1985;55:1332-8.
27. Gerber TC, Nishimura RA, Holmes DR Jr, et al. Left ventricular and biventricular pacingin congestive heart failure. Mayo Clin Proc 2001;76:803-12.
28. Hultgren HN, Craige E, Fujii J, Nakamura T, Bilisoly J. Left bundle branch block and mechanical events of the cardiac cycle. Am J Cardiol 1983;52:755-62.
29. Sadaniantz A, Saint Laurent L. Left ventricular Doppler diastolic filling patterns in patients with isolated left bundle branch block. Am J Cardiol 1998;81:643-5.
30. Xiao HB, Lee CH, Gibson DG. Effect of left bundle branch block on diastolic function in dilated cardiomyopathy. Br Heart J 1991;66:443-7.
31. Stevenson WG, Stevenson LW. Prevention of sudden death in heart failure. J Cardiovasc Electrophysiol 2001;12:112-4.
32. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol 2002;39:138-41.
33. Brutsaert DL, Sys SU. Diastolic dysfunction in heart failure. J Card Fail 1997;3:225-42.
34. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-21.
35. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. II. Causal mechanisms and treatment. Circulation 2002;105:1503-8.
36. Senni M, Redfield MM. Heart failure with preserved systolic function: a different natural history? J Am Coll Cardiol 2001;38: 1277-82.
37. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
38. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001;345:574-81.
39. Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221-7.
40. Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med 2000;160:1585-94.
41. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46. [Erratum, Arch Intern Med 1998;158:573.]
42. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes. I. General concepts. Circulation 2002;105:1727-33.
43. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. [Erratum, BMJ 1999;318: 29.]
44. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. [Errata, N Engl J Med 2000;342:748, 1376.]
45. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. [Erratum, Lancet 2000;356:860.]
46. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
47. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under-recognized public health problem. Arch Intern Med 2000;160:777-84.
48. Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 2000;283:3095-101.
49. Coats AJ. Exercise training for heart failure: coming of age. Circulation 1999; 99:1138-40.
50. Munzel T, Keaney JF Jr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001;104:1571-4.
51. Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol 2001;37:1757-64.
52. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: 1450-6. [Erratum, JAMA 1995;274:462.]
53. Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytolkine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-7.
54. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 2000;36:2090-5.
55. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
56. Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:70-8. [Erratum, J Am Coll Cardiol 2002; 39:746.]
57. Farrell MH, Foody JM, Krumholz HM. Beta-blockers in heart failure: clinical applications. JAMA 2002;287:890-7.
58. Bristow M. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
59. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-80.
60. Havranek EP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy ofirbesartan in heart failure. J Am Coll Cardiol 1999;33: 1174-81.
61. Pitt B, Poole-Wilson PA, Segal R, et al. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
62. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
63. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
64. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
65. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
66. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
67. Ellison D. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994;23:623-43.
68. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95.
69. The Digitalis Investigation Group. The effect ofdigoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
70. Adams KF, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946-53.
71. Gomberg-Maitland M, Baran DA, Fuster V. Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist. Arch Intern Med 2001;161:342-52.
72. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344:873-80.
73. Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999;99:2993-3001.
74. Kerwin WF, Botvinick EH, O'Connell JW, et al. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol 2000;35: 1221-7.
75. Saxon LA, De Marco T. Cardiac resynchronization: a cornerstone in the foundation of device therapy for heart failure. J Am Coll Cardiol 2001;38:1971-3.
76. Stellbrink C, Breithardt O-A, Franke A, et al. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol 2001;391957-65.
77. Touiza A, Etienne Y, Gilard M, Fatemi M, Mansourati J, Blanc JJ. Long-term left ventricular pacing: assessment and comparison with biventricular pacing in patients with severe congestive heart failure. J Am Coll Cardiol 2001;39:1966-70.
78. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
79. Bitran D, Merin O, Klutstein MW, Od-Allah S, Shapira N, Silberman S. Mitral valve repair in severe ischemic cardiomyopathy. J Card Surg 2001;16:79-82.
80. Baumgartner WA. What's new in cardiac surgery. J Am Coll Surg 2001;192:345-55.
81. Bishay ES, McCarthy PM, Cosgrove DM, et al. Mitral valve surgery in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg 2000;17:213-21.
82. Raman JS, Hata M, Storer M, et al. The mid-term results ofventricular containment (ACORN WRAP) for end-stage ischemic cardiomyopathy. Ann Thorac Cardiovasc Surg 2001;7:278-81.
83. Starling RC, McCarthy PM, Buda T, et al. Results of partial left ventriculectomy for dilated cardiomyopathy: hemodynamic, clinical and echocardiographic observations. J Am Coll Cardiol 2000;36:2098-103.
84. Jessup M. Mechanical cardiac-support devices - dreams and devilish details. N Engl J Med 2001;345:1490-3.
85. Massie BM, Teerlink JR. Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined. Am J Med 2000;109:431-3.
86. Bouchart F, Tabley A, Litzler PY, Haas-Hubscher C, Bessou JP, Soyer R. Myocardial revascularization in patients with severe ischemic left ventricular dysfunction: long term follow-up in 141 patients. Eur J Cardiothorac Surg 2001;20:1157-62.
87. Keeling PJ, McKenna WJ. Clinical genetics of dilated cardiomyopathy. Herz 1994; 19:91-6.
88. Mestroni L, Giacca M. Molecular genetics of dilated cardiomyopathy. Curr Opin Cardiol 1997;12:303-9.
89. Roberts R, Brugada R. Genetic aspects of arrhythmias. Am J Med Genet 2000;97: 310-8.